Ontario Industry Updates Guest User Ontario Industry Updates Guest User

Genesys III raises most of $125 mln target from HarbourVest, other LPs

Aug 16, 2016 - TORNTO - Genesys Capital has collected almost three-quarters of the $125 million target set for its third venture fund, adding to the momentum felt of late in Canada’s life-sciences sector.

Genesys Ventures III initially closed at $90 million in committed capital, the Toronto firm said today. It is expected to reach its goal early next year, Managing Director Damian Lamb told PE Hub Canada. 

Should the fund reach its $125 million target, it will be the largest Genesys has raised in its 16-year history.

For the full article, click here

Read More
OBIO News Guest User OBIO News Guest User

CAAP & Pre-CAAP Companies: Medella Health, Shift Health, and NERv TEchnology Chosen as Top 10 Finalists in the 2016 INTERFACE Health Challenge X

AUG 15, 2016 – VANCOUVER - The Top 10 finishers in the 2016 INTERFACE Health Challenge X have been selected. INTERFACE Health Challenge X is the world’s only annual competition to discover the world’s best digital health innovators.

This year's challenge started on March 1st at HiMSS 2016 in Las Vegas with this Call to discover the world's best digital health innovators.

OBIO CAAP Companies Medella Heath & Shift Health were among the finalists, as well as Pre-CAAP comapny NERv Technology. 

For the full article, click here

 

Read More
Ontario Industry Updates Guest User Ontario Industry Updates Guest User

Tissue Regeneration Therapeutics Engineered Mesenchymal Stromal Cells Advance Monoclonal Antibody Therapy

August 15, 2016 Tissue Regeneration Therapeutics Inc. (TRT) today announced that a team of Canadian researchers has for the first time shown that TRT’s engineered mesenchymal stromal cell product (eTXP) can be used to deliver therapeutically useful monoclonal antibodies (mAbs) more effectively than administration of the mAbs themselves. The study appears this month, as a featured paper, in the journal STEM CELLS Translational Medicine.

For the full release click here

Read More
OBIO News Guest User OBIO News Guest User

CAAP Company: MyndTec's MyndMove™ Highlighted on CTV News

Former OBIO CAAP company MyndTec's MyndMove™ was highlighted on CTV News regarding brain-controlled robots helping paralyzed patients move again and the newly release study by Duke University, published in Nature.

MyndMove is already in use for upper body rehabilitation in parts of Canada.

"We have seen dramatic improvement in stroke and spinal cord patients,” said brainchild of MyndMove, Dr. Milos R. Popovic, the Toronto Rehab Institute Chair in Spinal Cord Injury Research and Professor in the Institute of Biomaterials and Biomedical Engineering at the University of Toronto.

For the video, click here

For the full text of the Duke study, click here

Read More
OBIO News Guest User OBIO News Guest User

Pre-CAAP: iMerciv Selected to Compete at This Years CNE Innovation Garage

Congratulations to OBIO Pre-CAAP company iMerciv on being selected to compete at this years CNE Innovation Garage from August 19th - 21st (Enercare Centre at the CNE). 25 innovators from across the province will come together to compete in 5 categories for $25,000 Grand Prize!

The iMerciv BuzzClip is an assistive device that caters to the orientation & mobility needs of blind, deaf-blind and visually impaired communities around the globe. 

The Bio-tech Competition takes place: Friday August 19 @ 3pm. Remember to tweet and use the hashtag #cdntech

Learn more about the CNE Innovation Garage here

Read More
Ontario Industry Updates Guest User Ontario Industry Updates Guest User

Spectral Announces Second Quarter Results

Aug 12, 2016 TORONTO - Spectral Medical Inc., (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the second quarter ended June 30, 2016.

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ('PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's only active and most innovative Phase III study in the area of septic shock.

For the full press release, click here

Read More
OBIO News Guest User OBIO News Guest User

PreCAAP Company: iamsick.ca featured in StartUp Here TORONTO

Stay Away from Me...I Am Sick

OBIO Pre-CAAP Company iamsick.ca knows that the last thing you want to do when you are sick is look for a family doctor, a walk-in-clinic or a nearby pharmacy.  The new app informs patients on what clinics are nearby (in your actual area) and pharmacies and to find out what clinics are accepting new patients (great when you move to a new area!) and book appointments online.

For the full article click here

Read More
OBIO News Guest User OBIO News Guest User

CAAP Company: Eve Medical's Eve Kit Highlighted on CBC News

Former OBIO CAAP company Eve Medical was highlighted on CBC News. The EVE Kit is gearing up to be ready for purchase online this fall!

"Canadian women may be able to self-administer tests for sexually transmitted infections from the comfort of their own homes, for less than $100." 

CEO Jessica Ching says, the hope is to make "it more convenient for women to test for HPV which could guard against cervical cancer."

Follow their progress and updates on Twitter @evemedical

For the CBC feature click here

Read More
OBIO News Guest User OBIO News Guest User

Pre-CAAP: Winterlight Labs, SensOR Medical Laboratory, TopSpin360, iMerciv - Winners of 2016 ONtrepreneurs Program

Aug 8, 2016 - 4 OBIO Pre-CAAP companies have been selected as winners of the Ontario Brain Institute (OBI) 2016 ONtrepreneurs Program!

Congratulations to  Winterlight Labs, SensOR Medical Laboratory, TopSpin360 & iMerciv!

The ONtrepreneurs (Ontario Neurotech Entrepreneurs) Program helps "Ontario neurotech entrepreneurs take their ideas from the lab to the marketplace."

This year's winners participated in a pitching competition to a panel of "expert judges from organizations including Yocto Law, Biomedical Zone, Emmetros, AGE-WELL, Ironstone Product Development Inc. and OBI."

$300,000 ($50,000 each) has been awarded to the winners to assist with commercializing their neurotechnologies.

For the full press release, click here

 

Read More
OBIO News Guest User OBIO News Guest User

CAAP Company: CellAegis' autoRIC® Device Clinically Implemented in Peel-Halton Region

CellAegis autoRIC® Device, which reduces heart damage in ischemic heart disease, is now being clinically implemented in Peel-Halton Region, West of Toronto. The autoRIC® Device is being used to treat all patients having heart attacks, in addition to standard treatment. The FIRST study (Field Implementation of autoRIC Device in STEMI (ST-segment Myocardial Infarction)) is the first clinical implementation of our device across an entire region, and is expected to be the first of many such clinical implementations, as the benefit of Remote Ischemic Conditioning therapy becomes more widely utilized.

For the full press release click here

Read More
OBIO News Guest User OBIO News Guest User

CAAP Company: KA Imaging Receives $1M to develop low-cost lung screening

July 21, 2016 KITCHENER — A startup developing a low-cost, high-resolution digital X-ray imager to detect lung disease in developing nations has received a $1-million boost.

The new money from federally funded Grand Challenges Canada will help KA Imaging build a prototype and test it in the field in Zambia by the end of the year.

For the full article click here

For the Grand Challenges press release, click here

Read More
OBIO News Guest User OBIO News Guest User

OBIO Innovation Agenda Leader

OBIO Innovation Agenda Leader

On July 21st, Gail Garland, CEO of OBIO attended the  Federal Government's Global Science Excellence Roundtable, part of the Inclusive Innovation Agenda Strategy held in Ottawa.

The ideas generated during the session will be consolidated and presented to Minister Navdeep Bains for consideration as part of the Inclusive Innovation Agenda report.

For the full report, click here

For the Innovation Submission page, click here

Read More
OBIO News Guest User OBIO News Guest User

CAAP Company: iTP Biomedica Launches BladderPredict, A State-Of-The-Art Diagnostic To Manage Early Stage Bladder Cancer

July 19, 2016 TORONTO – iTP Biomedica Corp., a developer of proprietary whole transcriptome-based cancer diagnostics, today announced the launch of BladderPredict, a groundbreaking next-generation sequencing-based test that will for the first time assist uro-pathologists in assigning disease grade in early stage bladder cancer, and urologists and uro-oncologists in managing the disease.

For the full press release, click here

Read More
Ontario Industry Updates Guest User Ontario Industry Updates Guest User

Synaptive Medical Receives Health Canada Approval For Brightmatter Guide: A Surgical Navigation Solution

July 5, 2016 TORONTO – Synaptive Medical Inc., a company focused on global commercialization of innovative solutions, announced the approval from Health Canada to market BrightMatterTM Guide. This new technology is part of a solution for health care providers that includes informatics, imaging, surgical planning, navigation and advanced optics.

Read More